Biomarker discovery may improve schizophrenia treatment
Northwestern University scientists have identified a circulating brain protein biomarker that is significantly reduced in schizophrenia patients and developed a synthetic therapeutic that corrected abnormal brain activity in preclinical models, offering hope for treating the disorder’s debilitating cognitive symptoms.
For decades, schizophrenia treatment has focused on controlling what patients see and hear—but not how they think.
Now, researchers at Northwestern University may have uncovered something far more significant: a biological key to the cognitive symptoms that keep millions from living independently.
Already a member? Sign in
